EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, VivoSim Labs's enterprise value is €-0.77 Mil.
VivoSim Labs's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.38 Mil. Therefore, VivoSim Labs's EV-to-EBITDA for today is 2.04.
The historical rank and industry rank for VivoSim Labs's EV-to-EBITDA or its related term are showing as below:
FRA:4OR'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -9.7 Med: -0.98 Max: 3.62
Current: 0.89
During the past 13 years, the highest EV-to-EBITDA of VivoSim Labs was 3.62. The lowest was -9.70. And the median was -0.98.
FRA:4OR's EV-to-EBITDA is ranked better than 80.31% of 391
companies
in the Biotechnology industry
Industry Median: 13.38
vs FRA:4OR: 0.89
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
VivoSim Labs (FRA:4OR) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
VivoSim Labs's PE Ratio (TTM) for today is calculated as:
VivoSim Labs's share price for today is €3.492.
VivoSim Labs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.829.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for VivoSim Labs's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4OR vs SLXN, CDT, CLDI: EV-to-EBITDA Comparison
For the Biotechnology subindustry, VivoSim Labs's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VivoSim Labs EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, VivoSim Labs's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where VivoSim Labs's EV-to-EBITDA falls into.
VivoSim Labs's current Enterprise Value is €-0.77 Mil.
VivoSim Labs's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.38 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VivoSim Labs (FRA:4OR) has a EV-to-EBITDA of 2.04 as of Jul. 07, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on VivoSim Labs. According to the industry distribution chart, VivoSim Labs ranks #77 out of 391 companies in the Biotechnology industry, placing it in the top 19.7%.
Is VivoSim Labs' EV-to-EBITDA too high?
VivoSim Labs' current EV-to-EBITDA is 2.04. The Biotechnology industry median EV-to-EBITDA is 13.38. VivoSim Labs' value of 2.04 is 84.8% below this industry median. Based on the distribution chart, VivoSim Labs ranks #77 out of 391 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, VivoSim Labs has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does VivoSim Labs' EV-to-EBITDA compare to SLXN and CDT?
According to the Biotechnology industry distribution chart, VivoSim Labs ranks #77 out of 391 companies for EV-to-EBITDA. This places VivoSim Labs in the top 20% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.38. VivoSim Labs' value of 2.04 is 84.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.38, based on 391 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. VivoSim Labs's current EV-to-EBITDA of 2.04 is 84.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on VivoSim Labs. For the Biotechnology industry, the median EV-to-EBITDA is 13.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VivoSim Labs's current EV-to-EBITDA is 2.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VivoSim Labs stock overvalued right now?
VivoSim Labs (FRA:4OR) has a current EV-to-EBITDA of 2.04. The stock's GF Value™ is €9.41, compared to a current price of €3.49 — trading 62.9% below its estimated fair value. The current EV-to-EBITDA is 2.04 and 84.8% below the Biotechnology industry median of 13.38. VivoSim Labs' overall GF Score™ is 38/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current EV-to-EBITDA is 2.04 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is VivoSim Labs (FRA:4OR) Overvalued in 2026?
Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued.
The current stock price of €3.49 is trading 62.9% below its estimated GF Value™ of €9.41.
Key valuation signals for FRA:4OR:
EV-to-EBITDA: 2.04
GF Value™: €9.41 vs. price of €3.49 (62.9% below fair value)
Industry Position: 84.8% below the Biotechnology median (#77 of 391)
No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
38GF Score
Get the complete analysis for FRA:4OR
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4OR has been successfully added to your 
